Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Kw3357

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 3 (1)

Trial Status

Completed1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT04918173Phase 3RecruitingPrimary

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

NCT00938288Phase 1CompletedPrimary

A Study of KW-3357 in Congenital Antithrombin Deficiency

Showing all 2 trials

Research Network

Common Treatments

  • Kw33571
  • Atenativ1
  • Human Plasma Derived Antithrombin1

Active Sponsors

  • Kyowa Kirin Co., Ltd.1
  • Octapharma AG1
  • Kyowa Hakko Kirin UK, Ltd.1
  • Octapharma1

Top Investigators

Activity Timeline